Prior Authorization Review Panel MCO Policy Submission
|
|
- Marlene Banks
- 5 years ago
- Views:
Transcription
1 Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review. Plan: Aetna Better Health Submission Date: 10/01/2018 Policy Number: 0173 Policy Name: Prothrombin Time (INR) Home Testing Devices Effective Date: Revision Date: Type of Submission Check all that apply: New Policy* Revised Policy Annual Review No Revisions *All revisions to the policy must be highlighted using track changes throughout the document. Please provide any clarifying information for the policy below: CPB 0173 Prothrombin Time (INR) Home Testing Devices Policy is new to Aetna Better Health of Pennsylvania. Name of Authorized Individual (Please type or print): Signature of Authorized Individual: Dr. Bernard Lewin, M.D. New 10/01/2018
2 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 1 of 16 --> ( Prothrombin Time (INR) Home Testing Devices Number: 0173 *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Policy Aetna considers prothrombin time home testing units/home INR testing (e.g., the Coag-Sense Self-Test PT/INR Monitoring System, the CoaguChek XS Plus System, and the INRatio 2 PT/INR Monitoring System) medically necessary durable medical equipment for persons who require chronic oral anticoagulation with warfarin for a mechanical heart valve, ventricular assist device, chronic atrial fibrillation, deep venous thrombosis, pulmonary embolism, venous embolism and thrombosis of deep vessels of lower extremity, or hypercoagulable states (e.g., antithrombin III deficiency, Factor V Leiden, protein C deficiency, and protein S deficiency, etc) when all of the following criteria are met: 1. The expected need for home INR testing is 6 or more months; and 2. The person must have been anticoagulated for at least 3 months prior to use of the home INR devices; and Policy His tory Last Review 07/28/2018 Effective: 09/22/1997 Next Review: 02/14/2019 Review History Definitions A dditiona l In form at ion Clinical Policy Bulletin Notes 3. Self-testing with the device should not occur more frequently than once a week.
3 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 2 of 16 Aetna considers prothrombin time home testing units experimental and investigational for all other indications (e.g., arterial embolism to the eye, atrial flutter, and Kawasaki disease) because its effectiveness for indications other than the ones listed above has not been established. Aetna considers additional hardware/software systems needed for down-loading data from prothrombin time home testing units to computers for the management of anticoagulation as not medically necessary convenience items. Background This policy is consistent with the conclusions of an assessment from the Centers for Medicare & Medicaid Services (CMS, 2008). Prothrombin time home testing systems are portable, batteryoperated instruments for the quantitative determination of prothrombin time from finger-stick whole blood. The monitoring device measures the time it takes an individual s blood to clot. A drop of blood is obtained by a finger-stick using a lancet. The drop of blood is placed on a test strip and analyzed by the device. The device displays both the PT and calculated international normalized ratio (INR). If the results are out of normal range, the individual usually is advised to retest to confirm and if the results remain abnormal, they contact their physician as soon as possible. These devices store of the most recent test results, which are date and time stamped, enabling the health care provider to review the results and monitor trends in the individual s oral anticoagulant therapy control. The goal of home PT monitoring is to help the individual maintain an INR in the desired therapeutic range. International Normalized Ratio (INR) is a system established by the World
4 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 3 of 16 Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for reporting the results of blood coagulation (clotting) tests. The INR is the ratio of the individual's prothrombin time compared to the mean prothrombin time for a group of normal individuals. The prothrombin time is the amount of time needed for a small amount of blood to clot. Examples of US Food and Drug Administration (FDA) approved devices for home self-monitoring PT/INR include, but may not be limited to: Alere INRatio 2 PT/INR Monitoring System; CoagCare System; CoaguChek XS System; INRatio Prothrombin Time Monitoring System; INRatio 2 Prothrombin Time Monitoring System; and ProTime Microcoagulation System. These portable testing devices are available by prescription for home use under a physician s supervision. The physician who prescribes a home PT monitor is responsible for the training and ongoing management of individuals who use these devices. Alternatives to home PT monitoring include visits to a laboratory facility or health care provider s office for drawing and testing of a venous blood sample. Physician consultation is advised to make an informed decision based on an individual s health needs. Home INR monitors are designed to aid in the management of high-risk patients taking oral anticoagulants. They require considerable patient training and compliance to be useful. Self-testing and/or self-management by the patient using home international normalization ratio (INR) monitors represent another model of care with the potential for improved outcomes as well as greater convenience. Selftesting may provide a convenient opportunity for increased frequency of testing when deemed necessary. The use of the same instrument may increase the degree of consistency in instrumentation, and self-testing provides the potential for greater knowledge and awareness of therapy which may lead
5 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 4 of 16 to improved compliance. There is, however, insufficient evidence comparing the effectiveness of patient selftesting and self-management using a home INR monitor to care provided by an anticoagulation management service. Ansell et al (2001) explained: "Although a growing number of studies indicate the superiority of patient PST [patient selftesting] or PSM [patient self-management of dose adjustments] over UC [usual care, i.e., patients managed by their usual physicians], there is little evidence comparing them to care provided by an AMS [anticoagulation management service (i.e., anticoagulation clinic)]. PST and PSM require special patient training to implement, and therapy should be managed by a knowledgeable provider. A definitive recommendation cannot yet be made as to the overall value of PST or PSM." In a randomized controlled trial, Gardiner and colleagues (2005) ascertained if patients can achieve accurate INR values through patient self testing (PST) by means of the CoaguChek S (Roche Diagnostics, Lewes, UK). The main outcome measurements were comparability of INR values obtained by PST and the hospital laboratory, patient acceptability as assessed by a questionnaire and anticoagulant control. A total of 84 subjects (53 men, 31 women; median age of 59 years), receiving long-term oral anticoagulation (warfarin), were recruited. Subjects were randomized to weekly self-testing or continuing 4-weekly hospital laboratory monitoring of INR. Comparison of INRs (n = 234) showed no significant differences between the CoaguChek (median INR 3.02) and laboratory testing (median INR 3.07). There was excellent correlation between the 2 methods (r = 0.95), with 85 % of CoaguChek results within 0.5 INR units of the laboratory method. On 4 occasions, differences of greater than 1 unit INR were obtained, but in each case the patient's anticoagulation was unstable (INR greater than 4.5 by both methods) and the differences in INR would not have altered patient management. The results showed that 87 % of patients found self-testing straightforward, 87 % were
6 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 5 of 16 confident in the result they obtained and 77 % preferred selftesting. These investigators concluded that PST is a reliable alternative to hospital clinic attendance and is acceptable to the majority of suitably trained patients. In 2002, CMS issued a national coverage determination for the use of home prothrombin time INR monitoring for anticoagulation management for patients with mechanical heart valves on warfarin. More recently, a CMS Decision Memorandum (2008) concluded that there is sufficient evidence of the effectiveness of home prothrombin time (INR) monitoring for patients with a mechanical heart valve, chronic atrial fibrillation, or deep venous thrombosis. The monitor and the home testing must be prescribed by a treating physician and the following requirements must be met: Self-testing with the device should not occur more frequently than once a week; and The patient continues to correctly use the device in the context of the management of the anticoagualtion therapy following initiation of home monitoring; and The patient must have been anticoagulated for at least 3 months prior to use of the home INR devices; and The patient must undergo an educational program on anticoagulation management and demonstrated the correct use of the device prior to its use in the home. Matchar and colleagues (2010) examined the effect of home testing of INR on clinical events in patients with atrial fibrillation or mechanical heart valves. These investigators randomly assigned 2,922 patients who were taking warfarin because of mechanical heart valves or atrial fibrillation and who were competent in the use of point-of-care INR devices to either weekly self-testing at home or monthly high-quality testing in a clinic. The primary end point was the time to a first major event (stroke, major bleeding episode, or death). Patients were followed for 2.0 to 4.75 years, for a total of 8,730 patient-
7 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 6 of 16 years of follow-up. The time to the first primary event was not significantly longer in the self-testing group than in the clinictesting group (hazard ratio, 0.88; 95 % confidence interval [CI]: 0.75 to 1.04; p = 0.14). The 2 groups had similar rates of clinical outcomes except that the self-testing group reported more minor bleeding episodes. Over the entire follow-up period, the self-testing group had a small but significant improvement in the percentage of time during which the INR was within the target range (absolute difference between groups, 3.8 percentage points; p < 0.001). At 2 years of follow-up, the self-testing group also had a small but significant improvement in patient satisfaction with anti-coagulation therapy (p = 0.002) and quality of life (p < 0.001). The authors concluded that as compared with monthly high-quality clinic testing, weekly self-testing did not delay the time to a first stroke, major bleeding episode, or death to the extent suggested by prior studies. These results do not support the superiority of self-testing over clinic testing in reducing the risk of stroke, major bleeding episode, and death among patients taking warfarin therapy. Bonaros et al (2004) stated that ventricular assist device (VAD) implantation is associated with impaired primary hemostasis and thromboembolic complications. Recently, a new generation of implantable continuous flow axial pumps was introduced into clinical application. To study the potential thrombogenic properties of this type of pump, these researchers applied extensive platelet monitoring. In their institution, 13 patients received the MicroMed DeBakey VAD as a bridge to transplantation. Routine coagulation tests (platelet count, activated partial thromboplastin time, prothrombin time, anti-thrombin III activity) and platelet function tests (whole blood aggregometry, thrombelastography, flow cytometry) were performed. No clinically relevant thromboembolic events were detected. No correlation was found between global function tests, platelet aggregation, and thrombelastography. No correlation was detected between platelet activation and hemolysis
8 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 7 of 16 parameters. Platelet aggregation and coagulation index were significantly suppressed early after operation. A subsequent phase of hyper-aggregability, starting around day 6, suggested the initiation of anti-aggregation therapy. Platelet activation markers were up-regulated in the post-operative period but were returned to pre-operative levels after initiation of aspirin. In contrast to routine coagulation monitoring, platelet function tests reflect in detail the coagulation status of blood pump recipients and the efficiency of anti-aggregation therapy. Aspirin and dipyridamole therapy in addition to oral anticoagulation using phenprocoumon may contribute to platelet function and clot mechanics restoration and is, therefore, recommended for patients after VAD implantation. Joshi and colleagues (2007) noted that prothrombin time, expressed as INR and activated partial thromboplastin time (aptt), are standard methods of monitoring coumadin and heparin administration. Prothrombin activation fragment (F1.2) is an index of in vivo thrombin generation. These investigators hypothesized that F1.2 would provide a better surrogate of thromboembolism risk than standard coagulation assays during VAD support. In this study, INR, PTT and F1.2 were analyzed in 31 patients after implantation of a left-sided VAD daily during hospitalization and weekly after discharge. Thromboembolic events (TE) were defined by evidence of neurological injury revealed by plasma levels of S-100beta. The relationships between F1.2, INR for patients on coumadin and aptt for patients on heparin were evaluated from 1,250 observations of blood samples. S-100beta was positively correlated with F1.2, but not with INR and aptt. Correlation between S-100beta and F1.2 is significantly higher than with the other 2 markers (p < ). Higher values of aptt and INR were not associated with TE. Compared to conventional coagulation assays, the F1.2 level provides a single endpoint that is a more accurate predictor of TE after VAD implantation. The authors stated that further trials that incorporate the F1.2
9 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 8 of 16 marker into anti-coagulation algorithms may help reduce adverse events in this high-risk population. CPT Codes / HCPCS Codes / ICD-10 Codes Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+": Code Code Description CPT codes covered if selection criteria are met: Patient/caregiver training for initiation of home international normalized ratio (INR) monitoring under the direction of a physician or other qualified health care professional, face-to-face, including use and care of the INR monitor, obtaining blood sample, instructions for reporting home INR test results, and documentation of patient's/caregiver's ability to perform testing and report results Anticoagulant management for a patient taking warfarin, must include review and interpretation of a new home, office, or lab international normalized ratio (INR) test result, patient instructions, dosage adjustment (as needed), and scheduling of additional test(s), when performed HCPCS codes covered if selection criteria are met:
10 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins Aetna Page 9 of 16 Code Code Description G0248 Demonstration, prior to initial use, of home INR monitoring for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: face-to-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient ability to perform testing prior to its use G0249 G0250 Provision of test materials and equipment for home INR monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting of test results to physician; not occurring more frequently than once a week Physician review, interpretation and patient management of home INR testing for a patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes face-to-face verification by the physician that the patient uses the device in the context of the management of the anticoagulation therapy following initiation of the home INR monitoring; not occurring more frequently than once a week ICD-10 codes covered if selection criteria are met: D D68.62 Thrombophilia (Antithrombin III deficiency, Factor V leiden, Protein C deficiency, Protein S deficiency)
11 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 10 of 16 Code Code Description I I26.99 Pulmonary embolism I27.82 Chronic pulmonary embolism I48.0, Atrial fibrillation I48.2, I48.91 I I80.9 Phlebitis and thrombophlebitis of upper and lower extremities and unspecified site I I82.5Z9 Embolism and thrombosis of deep veins of lower extremity I I Acute embolism and thrombosis of deep veins of upper extremity I I Chronic embolism and thrombosis of deep veins of upper extremity T80.0XX+, Pulmonary embolism and infarction T , T81.72x+ T T [I26.90, I26.99 also required] Z95.2 Presence of prosthetic heart valve Z Presence of heart assist device ICD-10 codes not covered for indications listed in the CPB (not all-inclusive): H34.9 Unspecified retinal vascular occlusion [arterial embolism to the eye]
12 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 11 of 16 Code Code Description I48.1 Atrial flutter M30.3 Mucocutaneous lymph node syndrome [Kawasaki disease] The above policy is based on the following references: 1. No authors listed. Home monitoring for warfarin users. Health News. 1999;5(3):5. 2. No authors listed. A new approach to monitoring anticoagulation therapy: Testing prothrombin time at home. Harv Heart Lett. 1999;9(5): Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. In: Sixth ACCP Conference on Antithrombotic Therapy. Chest. 2001;119:22S-38S. 4. Poller L, Keown M, Chauhan N, et al. European Concerted Action on Anticoagulation--comparison of fresh plasma and whole blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole blood prothrombin time point-of-care monitors. Thromb Haemost. 2002;87(5): Nowatzke WL, Landt M, Smith C, Wilhite T, et al. Whole blood international normalization ratio measurements in children using near-patient monitors. J Pediatr Hematol Oncol. 2003;25(1): Center for Medicare and Medicaid Services (CMS). Prothrombin time (INR) monitor for home anticoagulation management (#CAG-00087N). National Coverage Analysis (NCA). Baltimore, MD: CMS; September 18, Horstkotte D, Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis. 2004;13(3):
13 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 12 of Tripodi A. Prothrombin time international normalized ratio monitoring by self-testing. Curr Opin Hematol. 2004;11(3): Jackson SL, Peterson GM, Vial JH, Jupe DM. Improving the outcomes of anticoagulation: An evaluation of home follow-up of warfarin initiation. J Intern Med. 2004;256(2): Yang DT, Robetorye RS, Rodgers GM. Home prothrombin time monitoring: A literature analysis. Am J Hematol. 2004;77(2): Gardiner C, Williams K, Mackie IJ, et al. Patient selftesting is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol. 2005;128 (2): Fitzmaurice DA. Oral anticoagulation control: The European perspective. J Thromb Thrombolysis. 2006;21(1): American Medical Association (AMA). Home anticoagulation monitoring. Report of the Council on Science and Public Health. Chicago, IL: AMA; Brown A, Wells P, Jaffey J, et al. Point-of-care monitoring devices for long-term oral anticoagulation therapy: Clinical and cost effectiveness. Technology Report No. 72. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); February Center for Medicare & Medicaid Services (CMS). Decision memo for prothrombin time (INR) monitor for home anticoagulation management (CAG R). Baltimore, MD: CMS; March 19, Centers for Medicare & Medicaid Services (CMS). National coverage determination (NCD) for home prothrombin time/international normalized ratio (PT/INR) monitoring for anticoagulation management (190.11). Baltimore, MD: CMS; March 19, Bradbury MJ, Taylor G, Short P, Williams MD. A comparative study of anticoagulant control in patients on long-term warfarin using home and hospital
14 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 13 of 16 monitoring of the international normalised ratio. Arch Dis Child. 2008;93(4): Ontario Ministry of Health and Long-term Care, Medical Advisory Secretariat (MAS). Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: An evidence-based analysis. Ontario Health Technology Assessment Series. 2009; 9(12): Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost. 2009;7(8): Plesch W, van den Besselaar AM. Validation of the international normalized ratio (INR) in a new point-ofcare system designed for home monitoring of oral anticoagulation therapy. Int J Lab Hematol. 2009;31 (1): Greenway A, Ignjatovic V, Summerhayes R, et al. Pointof-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rtf/95). Thromb Haemost. 2009;102(1): Sobieraj-Teague M, Daniel D, Farrelly B, et al. Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. Thromb Res. 2009;123 (6): Ryan F, O'Shea S, Byrne S. The reliability of point-ofcare prothrombin time testing. A comparison of CoaguChek S and XS INR measurements with hospital laboratory monitoring. Int J Lab Hematol. 2010;32(1 Pt 1):e26-e Dolor RJ, Ruybalid RL, Uyeda L, et al; THINRS Site Investigators. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA
15 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 14 of 16 Cooperative Study # The Home INR Study (THINRS). J Thromb Thrombolysis. 2010;30(3): Matchar DB, Jacobson A, Dolor R, et al; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17): Bonaros N, Mueller MR, Salat A, et al. Extensive coagulation monitoring in patients after implantation of the MicroMed Debakey continuous flow axial pump. ASAIO J. 2004;50(5): Joshi A, Magder LS, Kon Z, et al. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices. Interact Cardiovasc Thorac Surg. 2007;6(3): Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: Effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011;154(7): Nutescu EA, Bathija S, Sharp LK, et al. Anticoagulation patient self-monitoring in the United States: Considerations for clinical practice adoption. Pharmacotherapy. 2011;31(12): Holbrook A, Schulman S, Witt DM, et al.; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-84S. 31. National Institute for Health and Care Excellence (NICE). Atrial fibrillation and heart valve disease: Selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor). NICE Diagnostics Guidance 14. London, UK: NICE; September 24, 2014.
16 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 15 of DeSantis G, Hogan-Schlientz J, Liska G, et al. STABLE results: Warfarin home monitoring achieves excellent INR control. Am J Manag Care. 2014;20(3): Matchar DB, Love SR, Jacobson AK, et al. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015;40(1):17-25.
17 Prothrombin Time (INR) Home Testing Devices - Medical Clinical Policy Bulletins A... Page 16 of 16 Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change. Copyright Aetna Inc.
18 AETNA BETTER HEALTH OF PENNSYLVANIA Amendment to Aetna Clinical Policy Bulletin Number: 0173 Prothrombin Time (INR) Home Testing Devices There are no amendments for Medicaid. New 10/01/2018
Clinical Policy Title: Prothrombin international normalized ratio self-testing
Clinical Policy Title: Prothrombin international normalized ratio self-testing Clinical Policy Number: 05.01.02 Effective Date: July 1, 2013 Initial Review Date: April 23, 2013 Most Recent Review Date:
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationClinical Policy Title: Prothrombin international normalized ratio self-testing
Clinical Policy Title: Prothrombin international normalized ratio self-testing Clinical Policy Number: 05.01.02 Effective Date: July 1, 2013 Initial Review Date: April 23, 2013 Most Recent Review Date:
More informationClinical Medical Policy Department Clinical Affairs Division DESCRIPTION
Prothrombin Time/International Normalized Ratio (PT/INR) Monitor for Home Anticoagulation Management [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr.
More informationMEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME MONITORING DEVICE. POLICY NUMBER: CATEGORY: Equipment/Supplies
MEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME 06/23/16, 6/22/17 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationEvaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System
Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System Grace DeSantis, PhD Lisa Croner, PhD Michealle Havenhill, BA Shari Kipp, BSc (Honours) MBA Inverness Medical,
More informationDiagnostics Assessment Programme. Final scope
Diagnostics Assessment Programme Self-monitoring coagulometers (CoaguChek XS system, INRatio2 PT/INR monitor and ProTime Microcoagulation system), for selftesting or self-managing coagulation status in
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
THEME: EFFECTIVENESS OF INRatio2 PT/INR MONITOR Comment Name and number organisation 1. Consultee 10: Alere Section number Section1 Comment We do not agree that the INRatio2 PT/ INR monitor is only recommended
More informationDisclosures. Point of Care Testing (POCT) for Anticoagulation Monitoring. Point of Care Anticoagulation Monitoring. Questions.
Point of Care Testing (POCT) for Anticoagulation Monitoring Paula J. Santrach MD Consultant, Division of Transfusion Medicine Associate Professor, Laboratory Medicine Mayo Clinic Rochester, M Disclosures
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: CP.PHAR.225
Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationDiagnostic Technology: Point-of-Care International Normalised Ratio coagulometers for self-management of oral anticoagulation.
Horizon Scan Report 0012 20 December 2010 Diagnostic Technology: Point-of-Care International Normalised Ratio coagulometers for self-management of oral anticoagulation. Clinical Question: In patients who
More informationClinical Policy Bulletin: Nusinersen (Spinraza)
Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen
More informationI know my value CoaguChek XS Pro system
I know my value CoaguChek XS Pro system The smart way to manage your anticoagulation clinic CoaguChek XS Pro system A barcode scanner can make a difference There has been an extraordinary increase in the
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEDUCATIONAL COMMENTARY ORAL ANTICOAGULANT THERAPEUTIC MONITORING AND POINT-OF-CARE TESTING
POINT-OF-CARE TESTING Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Continuing Education on
More informationI know my value. Be an active part of your anticoagulation therapy with INR self-monitoring
I know my value Be an active part of your anticoagulation therapy with INR self-monitoring INR* self-monitoring needs only a drop of blood, is easy, fast and decreases the possibility Be involved in your
More informationClinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity
Clinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity Clinical Policy Number: 02.01.13 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationInternal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationProthrombin Time Home Testing Systems
Medical Coverage Policy Effective Date... 6/15/2017 Next Review Date... 6/15/2018 Coverage Policy Number... 0109 Prothrombin Time Home Testing Systems Table of Contents Related Coverage Resources Coverage
More informationClinical Policy: Total Artificial Heart Reference Number: CP.MP.127
Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationExcessive anticoagulation identified by emergency medical service through point-of-care coagulometry
Excessive anticoagulation identified by emergency medical service through point-of-care coagulometry BY CHRISTOPHER BEYNON, ANGELINA G ERK, STEFAN MOHR, FELIX HEISER, ERIK POPP Abstract Bleeding because
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationPrimary care. Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods.
Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods Leon Poller, Michelle Keown, Nikhil Chauhan, Anton M H P van den Besselaar, Armando
More informationDiagnostics guidance Published: 24 September 2014 nice.org.uk/guidance/dg14
Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) Diagnostics guidance Published: 24 September 2014 nice.org.uk/guidance/dg14
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationWe are writing to inform you about an issue concerning your CoaguChek system and test strips. Please read this information carefully.
Consumer Letter (CoaguChek XS PT Test PST, CoaguChek XS PT Test, CoaguChek PT Test) Urgent Field Safety Notice Location, Date We are writing to inform you about an issue concerning
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13, 12/18/14
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationMulti-targeted Antithrombotic Therapy for Total Artificial Heart Device Patients: a case series
Multi-targeted Antithrombotic Therapy for Total Artificial Heart Device Patients: a case series Angeleah Ramirez BS 1 Jeff Riley CCP Lyle Joyce MD 1. Second year perfusion student - Midwestern University
More informationRevalidation of CoaguChek XS Plus System for INR Monitoring in Taiwanese Patients: Effects of Clinical and Genetic Factors
Original Article 380 Revalidation of CoaguChek XS Plus System for INR Monitoring in Taiwanese Patients: Effects of Clinical and Genetic Factors Chao Hua Fu 1, Wei Ting Chen 2, Pi Yueh Chang 1,3, Ming Ta
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More information6 semanas de embarazo. Critical pt inr levels. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Critical pt inr levels INR is the result of the patient PT/mean normal PT, exponentially equalized by the ISI. INR levels above 4.9 are considered
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationSelf-testing and self-management of oral anticoagulation therapy in children
Review Article Schattauer 2011 391 Self-testing and self-management of oral anticoagulation therapy in children Thomas Decker Christensen 1 ; Torben Bjerregaard Larsen 2 ; Vibeke E. Hjortdal 1 1 Department
More informationUnstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.
Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationPoint of Care Testing for INR using CoaguChek XS Plus
Point of Care Testing, Pathology Page 1 of 18 Point of Care Testing for INR using CoaguChek XS Plus EDITION No 1.4 DATE OF ISSUE Feb 2014 REVIEW INTERVAL AUTHOR LOCATION OF COPIES 3 YEARS D O Neill 1.
More informationClinical Audit of Warfarin Clinic the 4 th Practice Mallow Primary Healthcare Centre,
Clinical Audit of Warfarin Clinic the 4 th Practice Mallow Primary Healthcare Centre, 2011-2012 Stephanie Cronin, Elaine Mulcahy, Dr David Molony, Curtis Irvine Introduction Methods Conclusion Warfarin
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationMEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE SUBUNIT CI (VKORC) THAT AFFECT RESPONSE TO WARFARIN
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationCryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
More informationNumber: Policy *Please see amendment for Pennsylvania Medicaid at the end. Last Review 06/09/2016 Effective: 08/14/2001 Next Review: 06/08/2017
1 of 6 Number: 0552 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers laser peripheral nerve block (laser neurolysis) experimental and investigational for any
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationOral Anticoagulation Therapy in Children: Successfully Controlled by Self-Management
7 (4), 2004 [Epub July 2004] doi:10.1532/hsf98.20041000 Online address: www.hsforum.com/vol7/issue4/2004-1000.html Oral Anticoagulation Therapy in Children: Successfully Controlled by Self-Management Thomas
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14, 09/15/15,09/21/17. THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY REVISED DATE: 06/26/14, 09/15/15,09/21/17. PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationPNEUMATIC COMPRESSION DEVICES IN THE HOME SETTING
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-60 Effective Date: 05/19/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationP oint of care testing (POCT) whole blood monitors are
114 ORIGINAL ARTICLE European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors L Poller, M
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationHuman Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC
Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC Ayman Kafal Medical Affairs, Leader CSL Behring Canada 1 Prothrombin Complex
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationClinical Policy: Homocysteine Testing Reference Number: CP.MP.121
Clinical Policy: Reference Number: CP.MP.121 Effective Date: 08/16 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationIncorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose
Intravenous Heparin Therapy Initial Dose (Max Dose) IV Infusion Rate IV Infusion Rate (Max Dose) Lab Tests High Dose 80 units/kg 8,000 units 18 units/kg/hr 1,800 units/hr Intermediate Dose 5,000 units
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationIcd 10 code for deep venous
Icd 10 code for deep venous thrombosis prophylaxis The Borg System is 100 % Icd 10 code for deep venous thrombosis prophylaxis PE. Pulmonary Embolus. F-10a Factor 10a Inhibitors. PH. Pulmonary. Hypertension.
More informationVitamin K antagonist (VKA) therapy is routinely
International Normalized Ratio Versus Plasma Levels of Coagulation Factors in Patients on Vitamin K Antagonist Therapy Gene Gulati, PhD; Megan Hevelow, MS; Melissa George, DO; Eric Behling, MD; Jamie Siegel,
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationHEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS
1 of 6 Policy #: 800 (PLH-800-13) Initiated Date: 12/4/2002 Reviewed Date: 8/1/2016 Subject: HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS Approved by: Laboratory Director, Jerry Barker (electronic signature)
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More information